Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Becton, Dickinson and Company

Market Cap 38.77B 33.88B 31.34B 29.25B 54.91B 3,664B 55.31B 372B 145B 1,801B 146B 142B 6,258B P/E 2026 *
35.1x
P/E 2027 * 27.1x
Enterprise Value 54.73B 47.82B 44.23B 41.29B 77.5B 5,172B 78.07B 526B 205B 2,543B 205B 201B 8,833B EV / Sales 2026 *
2.85x
EV / Sales 2027 * 2.68x
Free-Float
74.04%
Yield 2026 *
2.74%
Yield 2027 * 2.78%
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-5.43% - - 39.67B
-0.66%-0.95%-33.96%-18.86% 154B
-0.09%-1.38%-8.19%-9.31% 102B
-0.32%-0.57%+58.20%+60.13% 56.51B
-0.20%-3.61%-7.62%+44.40% 52.89B
-3.42%-7.02% - - 30.39B
-4.69%-6.94%-13.66%-45.41% 27.96B
+0.54%-0.52%+52.77%-10.57% 23.17B
-2.21%-1.10%-17.93%-3.92% 20.35B
-1.09%-2.69%-14.97%-5.57% 19.75B
Average -1.20%-1.69%+1.83%+1.36% 54.06B
Weighted average by Cap. -0.80%-1.31%-6.56%+0.42%

Financials

2026 *2027 *
Net sales 19.21B 16.78B 15.52B 14.49B 27.2B 1,815B 27.4B 184B 71.77B 892B 72.11B 70.54B 3,100B 19.71B 17.22B 15.93B 14.87B 27.91B 1,863B 28.12B 189B 73.66B 916B 74B 72.4B 3,181B
Net income 1.12B 983M 909M 848M 1.59B 106B 1.6B 10.8B 4.2B 52.25B 4.22B 4.13B 182B 1.45B 1.27B 1.17B 1.09B 2.05B 137B 2.07B 13.92B 5.42B 67.33B 5.44B 5.32B 234B
Net Debt 15.95B 13.94B 12.9B 12.04B 22.6B 1,508B 22.76B 153B 59.63B 741B 59.9B 58.6B 2,575B 14.07B 12.3B 11.37B 10.62B 19.93B 1,330B 20.08B 135B 52.59B 654B 52.83B 51.69B 2,271B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
140.71USD
Average target price
177.75USD
Spread / Average Target
+26.32%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!